Tuesday, 9 August 2022
  
Login

Australia's most trusted
source of pharma news

Tuesday, 09 August 2022
Listen to this story 
News

Sanofi throws down a trump card

 Posted 2 August 2022 PM

Sanofi has thrown down a trump card when it comes to getting ahead of its rivals, with the boss boasting it's the "least exposed" to generic competition of all the Big Pharmas right through to 2030.

CEO Paul Hudson said last week that 2023 marks the last patent cliff free fall for the company this decade, when its MS drug Aubagio opens to generic competition in the US. In Australia, the drug has been off patent since 2019.

To see the whole article, please login

Popular

Floodgates open on promotions
'New' GSK expanding Aussie team
Sales reps back from the dead
Rising Aussie star wins global gig
Latest Jobs
Pharma in Focus  Jobs

Sales & Customer Relations (11)

Clinical & Medical, R&D (11)

Regulatory, Pharmacovigilance & QA (5)

Devices (1)

Other (15)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2022 Lush Media | Privacy Statement | Subscribe to Pharma in Focus